Xencor to Present at Upcoming Investor Conferences

August 5, 2020 Off By BusinessWire

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate in three upcoming conferences:

  • BTIG Virtual Biotechnology Conference 2020

    Date:
    Monday, August 10, 2020

    Presentation Time: 12:00 p.m. ET / 9:00 a.m. PT
  • 2020 Wedbush PacGrow Healthcare Virtual Conference

    Date:
    Wednesday, August 12, 2020

    Presentation Time: 2:20 p.m. ET / 11:20 a.m. PT
  • Canaccord Genuity 40th Annual Growth Conference

    Date:
    Thursday, August 13, 2020

    Panel Time: 1:00 p.m. ET / 10:00 a.m. PT

A live webcast of the presentations at the BTIG and Wedbush conferences will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor. (Read more…)com. Replays will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 17 candidates engineered with Xencor’s XmAb® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Contacts

Charles Liles

626-737-8118

[email protected]

Media Contact

Jason I. Spark

Canale Communications

619-849-6005

[email protected]

Xencor to Present at Upcoming Investor Conferences

August 5, 2020 Off By BusinessWire

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate in three upcoming conferences:

  • BTIG Virtual Biotechnology Conference 2020

    Date:
    Monday, August 10, 2020

    Presentation Time: 12:00 p.m. ET / 9:00 a.m. PT
  • 2020 Wedbush PacGrow Healthcare Virtual Conference

    Date:
    Wednesday, August 12, 2020

    Presentation Time: 2:20 p.m. ET / 11:20 a.m. PT
  • Canaccord Genuity 40th Annual Growth Conference

    Date:
    Thursday, August 13, 2020

    Panel Time: 1:00 p.m. ET / 10:00 a.m. PT

A live webcast of the presentations at the BTIG and Wedbush conferences will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor. (Read more…)com. Replays will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 17 candidates engineered with Xencor’s XmAb® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Contacts

Charles Liles

626-737-8118

[email protected]

Media Contact

Jason I. Spark

Canale Communications

619-849-6005

[email protected]